Vivek Subbiah: AI for early cancer detection in Lancet Oncology
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), posted the following on LinkedIn:
“Nice review published in Lancet Oncology: ‘Artificial intelligence-aided data mining of medical records for cancer detection and screening.’
This review provides an overview of artificial intelligence methods designed to detect cancer early, including key aspects of concern (e.g., the problem of data drift—when the underlying healthcare data change over time), ethical aspects, and discrepancies between access to cancer screening in high-income countries versus low- and middle-income countries.”
Artificial intelligence-aided data mining of medical records for cancer detection and screening
Authors: Amalie Dahl Haue, MD PhD, Jessica Xin Hjaltelin, PhD, Peter Christoffer Holm, PhD, Davide Placido, PhD. Soren Brunak, PhD
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
More posts featuring Vivek Subbiah.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023